Hospital Universitario de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (58)

2024

  1. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

    Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387

2023

  1. Germline heterozygous exons 8–11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

    Hereditary Cancer in Clinical Practice, Vol. 21, Núm. 1

  2. Immunogenicity of COVID-19 vaccines in lung cancer patients

    Lung Cancer, Vol. 184

  3. Nurse-Supervised Exercise for People with Stage IV Cancer: The EFICANCER Randomized Clinical Trial

    Seminars in Oncology Nursing, Vol. 39, Núm. 4

2022

  1. Just an Acute Pulmonary Edema? Paraneoplastic Thyroid Storm Due to Invasive Mole

    Case Reports in Oncology, Vol. 15, Núm. 2, pp. 566-572

2021

  1. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

    Frontiers in Endocrinology, Vol. 12

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report

    Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1

  3. Malar bone metastasis of oncocytic neuroendocrine tumour of the lung

    Revista Espanola de Cirugia Oral y Maxilofacial, Vol. 41, Núm. 3, pp. 145-148

2018

  1. Infective endocarditis in a patient with metastatic colorectal cancer

    Revista Espanola de Quimioterapia

2017

  1. Hereditary pancreatic cancer: Related syndromes and clinical perspective

    Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1

2015

  1. Efficacy and safety of fixed-dose-rate infusions of gemcitabine plus erlotinib for advanced pancreatic cancer

    Journal of Analytical Oncology, Vol. 4, Núm. 1, pp. 44-51

  2. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

    BMC Cancer, Vol. 15, Núm. 1

  3. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Núm. 9, pp. 1378-1389

  4. Supervised physical exercise to improve the quality of life of cancer patients: The Eficancer randomised controlled trial

    BMC Cancer, Vol. 15, Núm. 1

2014

  1. Bevacizumab in combination with FOLFIRI in the first-line treatment of patients with advanced colorectal cancer: A single-institution experience

    Journal of Analytical Oncology, Vol. 3, Núm. 1, pp. 26-32

  2. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: Biological basis and therapeutic strategies

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 339-350

  3. Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer

    PLoS ONE, Vol. 9, Núm. 10

  4. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

    Oncology Research, Vol. 21, Núm. 4, pp. 181-191

  5. Tratamiento conservador del adenosarcoma mülleriano de cérvix uterino

    Progresos de Obstetricia y Ginecologia, Vol. 57, Núm. 2, pp. 83-87